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BACKGROUND: Mycosis fungoides (MF) is an indolent primary cutaneous T-cell lymphoma. To the authors’ knowledge, no data cur-
rently are available regarding the evolution over time of the risk of developing specific pathways of disease progression. METHODS:
This retrospective study analyzed 1422 patients with MF who were diagnosed and followed from 1975 through 2010 in 27 Italian Study
Group for Cutaneous Lymphoma centers. The primary objectives were to ascertain the time course, pathways, and hazards risk trends
of cutaneous/extracutaneous disease progression; to evaluate whether different tumor-lymph node-metastasis-blood (TNMB) stages
have different pathways of disease progression; and to analyze differences between tumor-stage and erythrodermic MF with regard
to clinical onset, disease evolution, and prognosis. The secondary objective was to provide a further validation for the revised Interna-
tional Society for Cutaneous Lymphomas and the Cutaneous Lymphoma Task Force of the European Organization of Research and
Treatment of Cancer (ISCL/EORTC) classification. RESULTS: The median follow-up was 14.5 years; stage progression occurred in
29.7% of patients and blood involvement was the most frequent extracutaneous site of disease progression. Patients with stage IA to
stage IB disease demonstrated a steady low annual incidence of disease progression to tumor-stage (1%-2%); patients with stage IIA
disease had a higher risk within the first years (up to 9.4%). Erythroderma evolved with a significantly higher frequency from
patches/plaques (13.9%/28.2%) than tumors (P ¼ .028 and P ¼ .013, respectively). Hazards rates of extracutaneous involvement were
low (< 1%). The T-score was found to be associated with extracutaneous involvement site, tumor-stage disease with lymph node/vis-
ceral lesions, and erythroderma with blood involvement. TNMB classification and stage progression resulted as independent
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prognostic variables being detected on multivariate analysis; the type of extracutaneous involvement was found to affect survival .
CONCLUSIONS: The data from the current study support the need for a stage-tailored follow-up, suggest that the classification of tu-
mor-stage disease at a stage below erythroderma could be modified, and offer a further validation for the revised TNMB classifica-
tion. Cancer 2012;000:000–000.VC 2012 American Cancer Society.
KEYWORDS: mycosis fungoides, cutaneous T-cell lymphoma, prognosis, tumor-lymph node-metastasis-blood (TNMB), classification,
erythroderma, tumor-stage, multivariate analysis.
INTRODUCTION
Mycosis fungoides (MF) is an indolent, primary, cutane-
ous T-cell lymphoma characterized by a proliferation of
small to medium-sized T lymphocytes with cerebriform
nuclei.1-3 It constitutes the most common cutaneous T-
cell lymphoma (53.7%4 to 72% of cases5), with an inci-
dence of 4.1 cases per 1 million.4 Clinical features are rep-
resented by long-standing, scaly, patch lesions
preferentially involving the buttocks and body areas infre-
quently exposed to sunlight (‘‘bathing trunk’’) and by a
slow evolution over years from patches to plaques and
eventually tumors or erythroderma.1-3,6-8 Lymph node
and visceral involvement, as well as large cell transforma-
tion,9-11 usually occur in the late stages of the disease;
moreover, patients with MF can develop typical manifes-
tations of Sezary syndrome (SS),1-3,12 so-called ‘‘second-
ary’’ SS.13 The prognostic relevance of the extent of skin
involvement and extracutaneous localizations has been
known since the 1970s, when the Mycosis Fungoides Co-
operative Group classification was developed.7,14 The re-
vision by the International Society for Cutaneous
Lymphoma (ISCL) and the Cutaneous Lymphoma Task
Force of the European Organization for the Research and
Treatment of Cancer (EORTC)6 brought significant
changes with respect to the previous classification,7
among them the prognostic relevance of the B (blood)
score. Indeed, a series of studies have demonstrated that a
B2 rating,15 as well as a hematologic stage of  3 accord-
ing to the suggested British classification,16,17 are associ-
ated with a poor prognosis.
However, the rarity of the disease has impaired the
collection of numerically representative patient series.18-25
To date, Kim et al19 and Zackheim et al20 have collected
data regarding 525 and 489 patients, respectively, with
MF. What to our knowledge is the largest study to date
was recently conducted on an impressive single-center
cohort of 1502 patients with MF/SS by Agar et al in the
United Kingdom.18 Multivariate analyses demonstrated
that advanced T-score, peripheral blood clonality, ele-
vated lactate dehydrogenase, and folliculotropic MF were
independent prognostic predictors of poor survival and an
increased risk of disease progression; large-cell transfor-
mation and tumor distribution (solitary, regional, and
disseminated) were associated with an increased risk of
disease progressions; and TNMB stage, age, male gender,
and a diagnosis of poikilodermatous MF were found to be
significant for overall survival.
A number of clinical questions still remain. Even if
it is generally accepted that MF evolves from patches to
plaques, nodules, and erythroderma, to the best of our
knowledge there are no data reported in the largest series
in the literature regarding the evolution of cutaneous
lesions and the pathways leading to advanced stage disease
and extracutaneous involvement. Second, the percentage
of stage progression from early phase disease ranges widely
from 9% to 34%.18-25 To the best of our knowledge, only
3 studies to date have reported disease progression risks
according to the clinical stage18,19,22; no data currently are
available concerning the evolution of the risk of develop-
ing specific pathways of disease progression (such as tu-
mor-stage, erythroderma, or blood/lymph node/visceral
involvement). Finally, the prognostic differences between
patients with tumor-stage and those with erythroderma
are still controversial: some articles have reported a similar
prognosis,18,20 whereas others have found a survival
advantage for erythrodermic23 or tumor-stage patients.21
Therefore, we decided to analyze the course of MF,
taking into consideration not only the clinical staging at
diagnosis but also the modifications of the cutaneous/
extracutaneous pattern of involvement as sequentially
observable during follow-up to identify the modalities of
disease progression rather than only the overall percentage
of patients in whom the disease progressed. A multicenter,
retrospective study was therefore designed to collect MF
cases diagnosed and followed between 1975 and 2010 in
dermatologic and hematologic institutions belonging to
the Italian Group of Cutaneous Lymphomas (Gruppo
Italiano Linfomi Cutanei [GILC]). The aims were to as-
certain the time course and pathways of cutaneous and
extracutaneous disease progression and the trends of asso-
ciated hazards rates over time; to evaluate whether differ-
ent TNMB stages of disease have not only different risks
of disease progression but also different pathways of dis-
ease progression; and to analyze the differences between
tumor-stage and erythrodermic MF in terms of clinical
onset, pathways of disease evolution, and prognosis. A
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secondary objective was to provide further clinical valida-
tion for the recently revised ISCL/EORTC classification.
MATERIALS AND METHODS
Patient Selection
A retrospective review of clinical data from patients with
MF collected from 1975 to 2010 in 27 GILC referral cen-
ters was performed. Inclusion criteria were: 1) a patho-
logic diagnosis of MF; 2) complete clinical information
and imaging obtained at the time of the initial diagnosis
(chest x-rays, abdominal ultrasound, computed tomogra-
phy, or positron emission tomography); and 3) clinical
and radiological follow-up of at least 1 year.
A diagnosis of MF was confirmed according to
ISCL/EORTC criteria2,3 and, if necessary, based on the
proposed algorithm for early phase disease.26 All patients
were reclassified according to the new ISCL/EORTC clas-
sification.6,27 Patients with evidence of cutaneous tumor
lesions at the time of first diagnosis were included only if
they also presented with patches and/or plaques. MF var-
iants (folliculotropic, pagetoid reticulosis, and granulom-
atous slack skin) were excluded because of their different
prognosis3 as well as patients with SS at the time of first
diagnosis. The development of SS (secondary SS13) dur-
ing follow-up was defined in the presence of erythro-
derma, palpable adenopathies, and peripheral blood
involvement according to ISCL recommendations.3,6,15
Transformation into high-grade lymphoma was defined
based on the presence of > 25% of large cells in skin
lesions.6,9-11 The pathologic diagnosis was made on the
basis of the (dermato)pathologist report; no review of bi-
opsy specimens was performed.
Cutaneous disease progression was based on hospital
reports and clinical photographs were reviewed whenever
available. Imaging procedures were comprised of chest x-
rays and abdominal ultrasound for patients with T1 to T2
disease, and computed tomography scans were performed
for patients with T3 to T4 disease. All the patients included
in the current study underwent imaging procedures at the
time of diagnosis and at least once yearly during follow-up.
Positron emission tomography was performed since 2002
in selected patients with T3 or T4 disease .
Lymph node/visceral involvement was defined by
pathological confirmation. Peripheral blood involvement
was defined by at least 1 of the following criteria15: 1)
absolute circulating Sezary cell counts of 1000/mm3; 2)
a CD4/CD8 ratio of  10; 3) increased lymphocyte
counts with evidence of a T-cell clone in the peripheral
blood by polymerase chain reaction; 4) a circulating
CD4þCD7- value of  40%; 5) aberrant expression of
T-cell markers; and 6) a chromosomally abnormal T-cell
clone. Disease progression was defined as a change in
TNMB stage with respect to initial diagnosis.
Table 1 summarizes the therapeutic approaches
according to clinical stage of disease. Phototherapy was
the mostly used treatment in patients with stage I and
stage II disease. Interferon, local radiotherapy, and mono-
chemotherapy were also administered in patients with
stage II disease. In those with stage III disease, interferon
was used in 23.4% and monochemotherapy in 22% of
patients. Extracorporeal photochemotherapy was per-
formed in 13.3% of patients with stage III disease and
16.7% of patients with stage IV disease. Monochemother-
apy or polychemotherapy were the most frequent treat-
ments for patients with stage IV disease.
Statistical Analysis
Data retrieved for each patient were: gender, age at diag-
nosis, time elapsed between the onset of cutaneous lesions
Table 1. Therapeutic Approaches On The Basis of Clinical Stage of Disease
Approach Stage I Stage II Stage III Stage IV
‘‘Wait and see’’ 13.8% — — —
Topical steroids 16.7% 3.3% 9.3% —
Phototherapy alone 43.2% 24.2% 9.2% 2.6%
Phototherapy and interferon 9.7% 3.3% 2.1% —
Phototherapy and retinoids 0.9% 3.3% 2.8% 3.1%
Acitretin 2.5% 2.6% — —
Bexarotene 0.2% 4.4% 9.2% 4.2%
Interferon 8.9% 12.1% 23.4% 10%
Local radiotherapy 2.3% 16.5% 2.1% 6.7%
Total-skin electron beam therapy 0.1% 1.8% — 3.3%
Monochemotherapya 1.7% 15.7% 22.0% 30.0%
Extracorporeal photochemotherapy — 7.7% 13.3% 16.7%
Polichemotherapyb — 5.1% 6.4% 23.3%
a Includes methotrexate, fludarabine, gemcitabine, and liposomal pegylated doxorubicin.
b CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-like regimens were administered to the majority of patients.
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and diagnosis, T-score and TNMB staging at the time of
the initial diagnosis according to the ISCL/EORTC, dis-
ease evolution over time (cutaneous and/or extracutaneous
disease progression, large cell lymphoma transformation,
development of SS), and maximum TNMB stage reached
during follow-up.
Nonparametric tests were applied to analyze the dif-
ferences in sample distribution. The Mann-Whitney U
test was used to evaluate the differences between 2 differ-
ent groups of patients at a set interval, and the Fisher exact
probability test was used for cross-table comparisons.
The hazard functions were used to evaluate the trends
in the risk of disease progression from early (stage IA/IB/
IIA) to advanced (stage IIB/III/IV) phase disease over time.
The hazard of progression of advanced phase disease was
defined as the probability per time unit that a patient with
early phase disease at the beginning of the respective inter-
val will progress to advanced phase disease during that
interval. It was computed as the number of advanced phase
disease progressions within the respective time interval di-
vided by the number of patients with early phase disease
entering the same time interval. The HRs were calculated
yearly, up to 5 years from the time of initial diagnosis and
then at the 10th and 15th years. The hazards differences
were analyzed using the Cochran test for linear trend.28
The primary endpoint for multivariate analysis was
overall survival (OS). OS was established from the time of
diagnosis until death, counting all deaths as events. Life-
table estimates of survival were derived by the Kaplan-
Meier method and compared statistically using the Mantel
stratified log-rank test.29 Multivariate OS analysis, strati-
fied for patient age at the time of first diagnosis, was per-
formed using the Cox proportional hazards regression
model with a stepwise selection of the significant varia-
bles.30 Variables included were gender, time interval
between the onset of cutaneous lesions and diagnosis,
TNMB stage at the time of initial diagnosis, stage progres-
sion during follow-up, transformation to high-grade lym-
phoma, and the development of SS during follow-up. The
variable ‘‘time interval between the onset of cutaneous
lesions and diagnosis’’ was continuous whereas the others
were categorical. The variables ‘‘stage progression,’’ ‘‘trans-
formation to high-grade lymphoma,’’ and ‘‘development
of SS’’ were included as time-dependent covariates. No
differences in OS were noted according to whether the
date of diagnosis was before or after 1995 and based on
center accrual number (> 50 patients or< 50 patients).
RESULTS
Clinical Data at the Time of Diagnosis
A total of 1422 patients were consistent with the inclusion
criteria. Demographic features demonstrated a male prev-
alence (male/female ratio of 1.72) and a median age at
first diagnosis of 59 years (range, 8 years-97 years). The
median age of the patients diagnosed with T4 disease (67
years; 25th-75th percentile: 54 years-73 years) was signifi-
cantly higher than that of others (59 years; 25th-75th per-
centile: 45 years-68 years) (P < .0001, Mann-Whitney U
test). Male prevalence within those patients diagnosed
with T4 disease (73.7%) was significantly higher than
that of other stages (58.2%) (P¼ .027, Fisher exact test).
The median time from the onset of cutaneous
lesions and diagnosis was 2 years. At the time of diagnosis,
the majority of patients (77.9%) had stage I disease (stage
IA in 38.8% and stage IB in 39.1% of patients). Stage IIB
disease was diagnosed in 5.5% of patients, and stage III in
6.6%. Extracutaneous involvement was documented at
the time of first diagnosis in only 0.8% of patients. With
regard to the T-score at the time of diagnosis, nearly one-
half of the patients (47.7%) had patches and/or plaques
on > 10% of their body surface; patches/plaques on <
10% of the body surface were found in 38.9% of patients,
whereas a minority of patients were found to have tumor
lesions or erythroderma.
Table 2. Disease Stage Progression According to the Initial Stage of Disease at Diagnosisa
Maximum stage IA IB IIA IIB IIIA IIIB IVA1 IVA2 IVB Disease
Stage
Progression
Stage at diagnosis
IA (n¼552) 412 (74.6%) 40 (7.2%) 20 (3.6%) 37 (6.7%) 16 (2.9%) 1 (0.2%) 12 (2.2%) 5 (0.9%) 9 (1.6%) 140 (25.4%)
IB (n¼556) 396 (71.2%) 24 (4.3%) 63 (11.3%) 29 (5.2%) 7 (1.3%) 14 (2.5%) 12 (2.2%) 11 (2.0%) 160 (28.8%)
IIA (n¼122) 73 (59.8%) 12 (9.8%) 12 (9.8%) 2 (1.6%) 9 (7.4%) 11 (9.0%) 3 (2.5%) 49 (40.2%)
IIB (n¼78) 44 (56.4%) 6 (7.7%) 0 10 (12.8%) 10 (12.8%) 8 (10.2%) 34 (43.6%)
IIIA (n¼82) 50 (61.0%) 7 (8.5%) 15 (18.3%) 7 (8.5%) 3 (3.7%) 32 (39.0%)
IIIB (n¼11) 5 (45.5%) 4 (36.4%) 2 (18.2%) 0 6 (54.5%)
IVA1 (n¼1) 1 0 0 —
IVA2 (n¼9) 8 (88.9%) 1 (11.1%) 1
IVB (n¼1) 1 –
a The number reported is the number of patients (percentages set in parentheses were calculated based on the total number of patients for each stage of dis-
ease). Gray-shaded cells represent patients who maintained the stage of disease noted at the time of the initial diagnosis to the end of the follow-up period.
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Incidences of Stage Progression and Maximum
Follow-Up Stage
Themedian follow-upwas 14.5 years (range, 1 year-35 years).
A stage progression occurred in 422 patients
(29.7%), with a significantly higher incidence for stage II
compared with stage I disease (P ¼ .001, Fisher exact
test). Table 2 summarizes the disease evolution according
to the initial stage in terms of maximum stage reached
during follow-up. Tumor-stage disease represented the
maximum stage in 6.7% to 11.3% of patients with stage
IA/IB/IIA disease at the time of initial diagnosis, whereas
erythroderma was less frequent. A small percentage of
patients (3.7%) developed erythroderma and blood
involvement, fulfilling the criteria for secondary SS.15
High-grade lymphoma transformation was noted in 3%
of patients. The cumulative percentage of progression to
advanced stage disease (stage IIB/III/IV) in patients diag-
nosed with early phase MF (stage IA/IB/IIA) was 21.5%,
ranging from 14.5% for stage IA to 40.1% for stage IIA
disease. The cumulative incidence of stage IV as the maxi-
mum disease stage reached during follow-up in patients
with stage IA/IB and IIA disease at the time of the initial
diagnosis ranged from 2.2% to 7.4% for stage IVA1 dis-
ease, from 0.9% to 9% for stage IVA2 disease, and only
up to 2.5% for stage IVB disease.
Significant differences were found with regard to
the distribution of the maximum stage of disease accord-
ing to the initial stage at diagnosis. Patients with stages
IB and IIA disease as their maximum stage demonstrated
a similar incidence of tumor lesions, whereas patients
with stage IIA disease had a significantly higher percent-
age of lymph node involvement (P ¼ .001). Patients
with stages IIA and IIB disease shared a similar incidence
of stage progression; however, those with stage IIB dis-
ease demonstrated a higher risk of extracutaneous
involvement and a lower incidence of erythroderma pro-
gression (P ¼ .001). Patients with stage III disease had a
higher incidence of hematological involvement and a
lower risk of visceral involvement than patients with
Figure 1. Distribution of cutaneous T scores at the time of extracutaneous involvement is shown.
Figure 2. T score evolution of patients with (a) T1 lesions and
(b) T2 lesions at the time of initial diagnosis is shown. The
number represents the percentage of patients who devel-
oped disease progression calculated based on the total num-
ber of patients whose disease progressed from either T1 or
T2. Gray-shaded areas at the left of each figure include those
patients whose cutaneous disease evolution spared  1 con-
secutive stages. The thickness of each line is proportional to
the number of patients who developed disease progression
after this specific evolution.
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stage IIB disease (P ¼ .05). These figures were confirmed
by the distribution of T-score at the time of extracutane-
ous involvement (Fig. 1). Stage IVA1 disease was found
to be significantly associated with erythroderma (45%; P
¼ .03), whereas lymph node and visceral involvement
were found to be significantly associated with the pres-
ence of tumor lesions (50% and 49%, respectively) (P ¼
.002).
Pathways of Cutaneous Disease Progression
The evolution of cutaneous disease is shown in Figures 2a
(T1 patients at the time of initial diagnosis) and 2b (T2
patients). The most frequent pattern for patients with T1
disease was the evolution to T2 and T3 disease (38.4% of
patients with T1 disease progressed); similarly, the most
common pathway of cutaneous evolution for patients
with T2 disease was T3 progression (62.7%). For both T1
and T2 patients, approximately 30% of patients (30.2%
for those with T1 and 28.2% for those with T2 disease)
had a cutaneous disease evolution sparing 1 consecutive
stages. In particular, T4 disease evolved with a signifi-
cantly higher frequency from either T1 or T2 disease
(13.9% and 28.2%, respectively) than from T3 disease (P
¼ .028 and P¼ .013, respectively).
Time Course of Cutaneous and Extracutaneous
Disease Progression
The hazards rate of progression to advanced disease are
shown in Table 3.
The hazards rate of disease progression to stage IIB
during the first year after diagnosis was significantly higher
in patients with stage IIA disease (9.4%) compared with
those with stage IA (2%) and IB (1.8%) disease (P ¼
.0001). Thereafter, patients with stage IA/IB disease demon-
strated a steady annual incidence of progression to stage IIB
disease (approximately 1% and 2%, respectively), which was
maintained until the 15th year; conversely, the incidence of
progression to stage IIB for patients with stage IIA disease
decreased significantly during the first 5 years (P ¼ .031,
Cochran test for linear trend), thereafter reaching steady val-
ues similar to those for stage IA and stage IB disease. A simi-
lar behavior was demonstrated for stage III progression, even
if the hazards values were lower than for stage IIB disease.
Patients with stage IIA disease demonstrated significantly
higher values since the first year after diagnosis (6.3%; P ¼
.002 vs stage IA/IB disease), and thereafter showed a pro-
gressive reduction; conversely, patients with stage IA and
stage IB disease presented with steady values during follow-
up. The hazards rates for extracutaneous involvement were
low (< 1%) and both stage IA/IB and stage IIA patients
maintained steady values during follow-up. Patients with
stage IIA disease demonstrated significantly higher hazards
rates during the first year after diagnosis (P < .001) for
blood/lymph node and visceral involvement.
OS and Validation of the Revised EORTC/ISCL
Staging System
OS according to the stage of disease at the time of the ini-
tial diagnosis is shown in Figure 3a. The 5-year and 10-
Table 3. Annual Hazard of Progression to Different Manifestations of Advanced Phase Disease According to the Initial Early
Phase Diagnosis
First Year Third Year Fifth Year 10th Year 15th Year
IA 2.0% 1.4% 1.1% 1.9% 1.9% To stage IIB
IB 1.8% 2.7% 1.8% 1.8% 1.2%
IIA 9.4% 6.1% 1.1% 1.3% 0.9%
All 2.6% 2.7% 1.5% 1.0% 1.0%
IA 1.2% 0.6% 0.5% 0.5% 0.4% To stage III
IB 0.6% 1.2% 0.3% 0.6% 0.5%
IIA 6.3% 3.6% 1.4% 1.1% 0.4%
All 1.4% 1.1% 0.4% 0.4% 0.5%
IA 0 0.5% 0.4% 0 0 To stage IVA1
IB 0.9% 0.7% 0.3% 0.5% 0
IIA 0.8% 1.3% 0.6% 0 0
All 0.5% 0.5% 0.1% 0.3% 0
IA 0.2% 0.2% 0.2% 0.4% 0 To stage IVA2
IB 0.3% 0.4% 1.0% 0.9% 1.0%
IIA 0.8% 0.4% 1.0% 0.9% 1.1%
All 0.5% 0.4% 0.6% 0.5% 0.7%
IA 0 0 0.3% 0.6% 0 To stage IVB
IB 0.2% 0 0.8% 0.6% 0
IIA 0.8% 1.0% 0.7% 0 0
All 0.2% 0.3% 0.5% 0.3% 0
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year survival rates were 97% and 93%, respectively, for
stage IA disease and decreased significantly to 91% and
86%, respectively, for stage IB disease (P ¼ .003); 79%
and 72%, respectively, for stage IIA disease (stage IB vs
stage IIA: P ¼ .0002); and 69% and 51%, respectively,
for stage IIB disease (stage IIA vs stage IIB: P¼ .014). No
differences were found between stage IIB and stage III dis-
ease, whereas patients with stage IV disease demonstrated
an extremely poor prognosis (5-year survival rate of 24%).
Survival rates were also calculated from the date of
diagnosis of each stage of disease during follow-up. No
differences were demonstrated between stage IIIA and
IIIB, whereas the distinction between stage IVA1, stage
IVA2, and stage IVB carried a relevant prognostic value
(Fig. 3b): patients with blood involvement were found to
have a better survival than those with lymph node/visceral
disease.
Multivariate OS analysis stratified for age identified
stage at the time of initial diagnosis (HR, 1.45) and stage
progression during follow-up (HR, 2.92) as variables with
independent prognostic relevance (Table 4).
DISCUSSION
The current study presents a retrospective analysis of clini-
cal and long-term follow-up data from 1422 Italian
patients with classic MF who were reclassified according
to the new ISCL/EORTC system.6,27 To the best of our
knowledge, the current series is the largest cohort of MF
patients together with that recently reported by the UK
group,18 which analyzed survival outcomes and prognos-
tic factors related to OS, disease-specific survival, and risk
of disease progression as calculated from an impressive
single-center cohort of 1502 patients with MF/SS . With
respect to that study, we did not include either patients
with MF variants or SS not preceded by MF13 to obtain a
more homogeneous patient cohort. Moreover, the follow-
up of the current study (median, 14.5 years) is to the best
of our knowledge longer than that of previously published
series (median, 3 years-6 years).18-25 The current study
differs from that of Agar et al18 in that our analysis was
focused on the patterns and time course of disease evolu-
tion over time to identify the pathways of cutaneous and
extracutaneous disease progression and to ascertain the
trends in the hazard risk of specific pathways of disease
evolution (development of tumors, erythroderma, or
blood/lymph node/visceral involvement). To the best of
our knowledge, no data have been reported in the litera-
ture regarding this topic in large patient cohorts, despite
its central relevance in the setting of clinically based,
adequate follow-up and therapeutic strategies.
The current study provides a quantification of the
risk and patterns of disease progression. A stage progres-
sion occurred in 29.7% of patients, which is similar to
data from the literature (25%-34%).18-25 Overall,
approximately 1 of 5 patients (20%) with early phase MF
developed disease progression to advanced phase during
follow-up, with a significantly higher percentage noted
for patients with stage IIA disease (40.1%; P ¼ .02).
Extracutaneous disease progression occurred in < 5% of
patients, 3.7% developed SS, and 3% experienced trans-
formation into high-grade lymphoma. MF demonstrates
an indolent clinical course18-25,31-32; however, to the best
of our knowledge, only a few studies to date have analyzed
disease progression risk over time or according to the clin-
ical stage of disease.18,19,22 Previous studies by Agar et
al,18 Kim et al,19 and van Doorn et al22 found an increase
in the overall risk of disease progression over time. We cal-
culated the hazards rates of progression to advanced dis-
ease in patients with an initial diagnosis of early phase
Figure 3. (a) Time-to-disease progression (TTP) is shown
from early stage disease (stage IA/IB/IIA) to advanced phase
disease. Each curve represents the TTP toward the reported
advanced stage disease (from stage IIB to stage IVB). (b)
Survival of patients with stage IV disease is shown.
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MF. Patients with stage IA/IB disease demonstrated a
low, steady annual incidence of progression to stage IIB
(approximately 1%-2% ) or stage III (0.5%-1%) disease,
which was maintained until the 15th year. Conversely,
patients with stage IIA disease demonstrated significantly
higher risk of disease progression to stage IIB or stage III
during the first year (9.4% and 6.3%, respectively,) fol-
lowed by a progressive decrease thereafter and reaching
steady values similar to stage IA/IB disease. The hazards
rates of extracutaneous involvement were low (< 0.5% to
1%) and both stage IA/IB and stage IIA patients main-
tained steady values during follow-up. The long-term
steady values of the hazard risk of disease recurrence justify
the need for a prolonged follow-up.
The results of the current study also confirm that
although TNM staging is associated with different pro-
gression rates,18,19,22 there is also a relationship with dif-
ferent patterns of disease progression. As already
reported,32 patients with stage IIA disease had an overall
higher rate of disease progression than patients with stage
IB disease, with the same rate of progression to tumor-
stage but a higher risk of lymph node involvement and
therefore a worse prognosis. Moreover, patients with stage
IIB disease demonstrated a higher percentage of extracuta-
neous involvement than those with stage IIA disease, de-
spite the similar overall rate of disease progression.
Tumor-stage MF demonstrates more frequent lymph
node and particularly visceral involvement compared with
extracutaneous disease progression, whereas erythroder-
mic MF mainly develops as hematological involvement
and thus transformation into SS. Approximately one-half
the patients with lymph node/visceral involvement dem-
onstrated tumor-stage disease at the time of extracutane-
ous disease progression, whereas 45% of patients with
blood involvement had erythroderma. These data empha-
size the need for differentiated follow-up strategies: close
radiological procedures for patients with tumor-stage MF,
whereas erythrodermic patients should be tested more fre-
quently for blood involvement. Some other literature data
are in agreement with the current study findings. de Con-
inck et al33 found that the majority of patients with stage
IV disease had tumor-stage cutaneous disease; however,
the authors did not analyze the presence of blood involve-
ment as a separate category. Diamandidou et al23 found
peripheral blood involvement occurring almost exclu-
sively in patients with T4 disease (78% of cases), whereas
in the Dutch study,22 patients with T3 disease were char-
acterized by a significantly higher risk of lymph node/vis-
ceral involvement.
The differences between tumor-stage (stage IIB) and
erythrodermic (stage III) MF involve not only the path-
ways of disease evolution but, in an earlier phase, their
clinical onset, as represented by additional new evidence
highlighted in the current study. We believe the current
study is the first to demonstrate that the evolution from
tumor-stage to erythroderma represents a very uncom-
mon feature. In fact, T4 erythroderma developed with a
significantly higher frequency from T1 or T2 disease than
from T3 disease, thus suggesting that evolution to T3 and
T4 disease follows two separate parallel rather than se-
quential clinical pathways. Patients with erythrodermic
MF are also characterized in the current series by demo-
graphic differences, most significantly by being signifi-
cantly older and with a more pronounced male
prevalence. Similar age differences between MF stages
have already been reported.19,20
The data from the current study provide clinical val-
idation for the revised TNMB classification,6 in agree-
ment with the study by Agar et al.18 The multivariate OS
analysis stratified for age identified TNMB classification
at the time of initial diagnosis and stage progression as a
time-dependent covariate during follow-up as independ-
ent prognostic variables. These results are fairly similar to
those reported by Agar et al,18 even if we did not confirm
the prognostic relevance of male gender. With respect to
Agar et al’s study,18 we did not include MF variants or SS
not preceded by MF to obtain a more homogeneous
patient cohort; moreover, we could not evaluate lactate
dehydrogenase values because they were available in only
a minority of patients. The clinical relevance of the newly
introduced split of stage IV into stage IVA1 (blood), stage
IVA2 (lymph node), and stage IVB (viscera) disease was
confirmed in the current study (as well as the study by
Agar et al18) through evidence of survival differences
according to the type of extracutaneous involvement. The
independent tracking of these 3 prognostic indicators is
Table 4. Multivariate Analysis of Survival
Variable SE HR 95% CI P
TNMB stage at diagnosis 0.0787088 1.448915 1.302577-1.611693 <.001
Stage progression during follow-up 0.4336843 2.922946 2.185376-3.909449 <.001
Abbreviations: 95% CI, 95% confidence interval; HR, hazards ratio; SE, standard error; TNMB, tumor-lymph node-metastasis-blood stage.
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clinically relevant to identify a homogeneous series of
patients and to evaluate a better therapeutic approach. We
could not confirm survival differences between patients
with stage IIIA and IIIB disease, most likely due to the
low number of patients with stage IIIB who were available
for analysis, consequent to the difficulties in the retrospec-
tive evaluation of B score. It is interesting to note that
patients with tumor-stage and erythrodermic disease, who
were characterized by different demographic features, pat-
terns of onset, and disease evolution, share a similar prog-
nosis without survival differences. Conflicting results have
been reported in the literature; a series of articles did not
detect any survival differences between these 2 groups,18-
20,25,34 whereas others demonstrated a worse prognosis for
patients with T3 disease.21,23,33 These data suggest that
the continued classification of tumor-stage at a stage
below erythroderma is not supported by clinical findings
and therefore could be modified.
In conclusion, the data from the current study
emphasize the need, from a biological point of view, to
understand the molecular basis of the different clinical
pathways of disease progression, whereas from a clinical
prospective, they support the relevance of a stage-tai-
lored, differentiated follow-up strategy. The prognostic
significance of the revised TNMB classification suggests
that the analysis of stage progression development repre-
sents a potential endpoint in the design of prospective
clinical trials.
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